Immatics (IMTX) Capital Expenditures (2019 - 2025)
Immatics recorded quarterly Capital Expenditures of -$1.1 million in Q4 2025, up 10.98% quarter-over-quarter from -$1.3 million in Q3 2025, and up 36.88% year-over-year from -$824903.9 in Q4 2024.
Immatics' Capital Expenditures history runs 7 years deep, the most recent figure standing at -$1.1 million for Q4 2025.
- In Q4 2025, Capital Expenditures rose 36.88% year-over-year to -$1.1 million; the TTM figure through Dec 2025 stood at -$7.2 million (up 58.95% YoY), while the FY2025 annual figure was -$7.4 million, up 57.39% from the prior year.
- Capital Expenditures came in at -$1.1 million for Q4 2025 at Immatics, up from -$1.3 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $56.3 million in Q4 2023 to a low of -$11.6 million in Q2 2023.
- A 5-year average of $386663.4 and a median of -$1.6 million in 2025 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures surged 545.09% in 2022 and sank 1248.09% in 2023, its largest moves.
- Immatics' Capital Expenditures stood at -$2.1 million in 2021, then soared by 545.09% to $9.3 million in 2022, then jumped by 504.3% to $56.3 million in 2023, then sank by 103.18% to -$1.8 million in 2024, then surged by 36.88% to -$1.1 million in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$1.1 million, -$1.3 million, and -$1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | -1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.13 Mn |
| Dec 31, 2025 | -1.13 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Jun 30, 2025 | -1.62 Mn |
| Jun 30, 2025 | -1.62 Mn |
| Mar 31, 2025 | -3.23 Mn |
| Mar 31, 2025 | -3.23 Mn |
| Dec 31, 2024 | -1.79 Mn |
| Dec 31, 2024 | -1.79 Mn |
| Sep 30, 2024 | -3.08 Mn |
| Sep 30, 2024 | -3.08 Mn |
| Jun 30, 2024 | -2.82 Mn |
| Jun 30, 2024 | -2.82 Mn |
| Mar 31, 2024 | -9.97 Mn |
| Mar 31, 2024 | -9.97 Mn |
| Dec 31, 2023 | 56.28 Mn |
| Dec 31, 2023 | 56.28 Mn |
| Sep 30, 2023 | -7.08 Mn |
| Sep 30, 2023 | -7.08 Mn |
| Jun 30, 2023 | -11.64 Mn |
| Jun 30, 2023 | -11.64 Mn |
| Mar 31, 2023 | -4.63 Mn |
| Mar 31, 2023 | -4.63 Mn |
| Dec 31, 2022 | 9.31 Mn |
| Dec 31, 2022 | 9.31 Mn |
| Sep 30, 2022 | -1.44 Mn |
| Sep 30, 2022 | -1.44 Mn |
| Jun 30, 2022 | -863,248.86 |
| Jun 30, 2022 | -863,248.86 |
| Mar 31, 2022 | -1.30 Mn |
| Mar 31, 2022 | -1.30 Mn |
| Dec 31, 2021 | -2.09 Mn |
| Dec 31, 2021 | -2.09 Mn |
| Sep 30, 2021 | -1.61 Mn |
| Sep 30, 2021 | -1.61 Mn |
| Jun 30, 2021 | -1.62 Mn |
| Jun 30, 2021 | -1.62 Mn |
| Mar 31, 2021 | -681,523.40 |
| Mar 31, 2021 | -681,523.40 |
| Dec 31, 2020 | 15.84 Mn |
| Dec 31, 2020 | 15.84 Mn |
| Sep 30, 2020 | -1.58 Mn |
| Sep 30, 2020 | -1.58 Mn |
| Jun 30, 2020 | -2.35 Mn |
| Jun 30, 2020 | -2.35 Mn |
| Mar 31, 2020 | -2.63 Mn |
| Mar 31, 2020 | -2.63 Mn |
| Dec 31, 2019 | -819,096.88 |
| Dec 31, 2019 | -819,096.88 |
| Sep 30, 2019 | -278,182.51 |
| Sep 30, 2019 | -278,182.51 |